BioSpace News Archive

Iveric Bio Announces New Post-Hoc Analyses of Zimura ® from GATHER1 Clinical Trial to Be Presented at Angiogenesis, Exudation, and Degeneration 2022.

Twist Bioscience Corporation and Eleven Therapeutics today announced that they have created a replicon tool that could be used for studying viral genome replication and antiviral drug screening as well as vaccine and therapeutic development.

Eyenovia, Inc. today announced changes to its Board of Directors.

Photocure ASA, The Bladder Cancer Company, announces U.S. Food and Drug Administration approval of a new and improved Blue Light system to be used with Photocure’s Cysview® product in Blue Light Cystoscopy procedures for the detection of NMIBC*.

Ondine Biomedical Inc., has treated the first patients in its nasal photodisinfection exploratory Phase 2 trial.

Active Biotech announced that the first patient has been dosed in the combination part of the phase Ib/IIa clinical study of tasquinimod in relapsed or refractory multiple myeloma.

Devyser Diagnostics AB, a Swedish molecular diagnostics company, announced that the company has utilized an option to acquire all of the remaining shares in the associated company SmartSeq S.r.l.

Nemysis Ltd announces the appointment of Antonino Santoro to its Executive Team as Adviser for Scientific Affairs.

Agendia, Inc. announced new data published in Genes, Chromosomes and Cancer that show MammaPrint® and BluePrint® gene signatures represent and capture all of the original 10 hallmarks of cancer, recognized as the biological capabilities acquired during the multi-step development of human cancer, as defined by Hanahan and Weinberg.1,2

Varsity Pharmaceuticals announced that it has secured exclusive rights from Dana-Farber Cancer Institute, a world-leading cancer treatment and research institute, to develop and commercialize Novobiocin, a potential first-in-class DNA polymerase theta inhibitor for the treatment of Homologous Recombination deficient cancers.